查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193310

止吐藥市場：按藥物類型、應用、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Antiemetics Market By Drug Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

全球止吐藥市場預計到 2021 年將達到 22.5168 億美元，到 2031 年將達到 40.6136 億美元，2022 年至 2031 年的複合年增長率為 6.1%。 .

排放，也稱為呼氣，是指物質不自主地、被迫地通過嘴或鼻子從胃中排出，而用於阻止這種不自主排出的藥物稱為止吐藥。 暈船、早孕、劇烈疼痛、接觸化學毒素、情緒壓力（恐懼）、膽囊疾病、食物中毒和消化不良等暈動病是嘔吐的一些常見原因。 化療、胃腸炎、全身麻醉、腸梗阻、偏頭痛等嚴重疾病也會導致患者噁心嘔吐。

化療的興起是推動止吐藥市場增長的主要因素之一。 根據美國癌症協會 (ACS) 的數據，美國預計 2022 年將有 609,360 例癌症死亡和 190 萬例新發病例。 男性和女性的癌症死亡率總和從 1991 年的高位下降到 2019 年的 32%。 死亡率的下降主要是由於接受各種癌症治療（包括化學療法和放射療法）的患者迅速增加。 化療和放療的使用預計會增加對止吐藥的需求，因為這些治療與噁心和嘔吐等副作用有關。 因此，預計在預測期內，癌症患者的高患病率和化療作為一種治療選擇的廣泛使用將推動全球止吐市場的發展。

此外，政府和私人實體增加對製造設備的資助也有望促進市場的增長。 世界各地的政府機構也提供資金進行新分子的研發，促進該地區的市場增長。 此外，主要市場參與者的收購和合作也在提振市場。 主要市場參與者主要採用這些關鍵策略來擴展業務和產品組合，從而導致公司銷售額隨著市場增長而增加。

此外，腸胃炎的爆發也促進了市場的增長。 胃腸炎是胃和腸道的炎症，通常是由感染了病毒、細菌和寄生蟲的食物和水引起的。 除了胃部不適和痙攣外，它還會引起噁心、發燒、抽搐和頭痛。 此外，諾如病毒是美國胃腸炎和食物中毒的突出病因，會引起患者噁心□□和嘔吐。 此類諾如病毒疫情增加了止吐藥的需求，增加了該地區止吐藥的銷量，帶動了整體市場的增長。

然而，止吐藥的低意識阻礙了市場增長。 此外，處方止吐藥的強度、劑量和治療類別會加劇患者的病情，需要對藥物及其藥理學有適當的了解，這可能會限制止吐藥市場。我有。 另一方面，主要市場參與者增加研發活動和醫療成本上升將進一步鼓勵許多主要參與者進入新興市場，為擴大止吐市場提供有利機會。我們提供機會。 此外，亞洲和LAMEA等新興市場豐富的原材料為市場參與者提供了有利可圖的投資機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章止吐藥市場：按藥物類型分類

  • 概覽
    • 市場規模和預測
  • 抗組胺藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 血清素受體拮抗劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 多巴胺受體拮抗劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 神經激□受體拮抗劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 抗膽鹼藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他藥物類型
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章止吐市場：按應用

  • 概覽
    • 市場規模和預測
  • 化療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 術後手術
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 懷孕/腸胃炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他用途
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章止吐市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 零售藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 在線藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章止吐市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按藥物類型
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按分銷渠道
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按藥物類型
    • 歐洲市場規模和預測：按應用分類
    • 歐洲市場規模和預測：按分銷渠道
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按藥物類型
    • 亞太地區的市場規模和預測：按應用分類
    • 亞太市場規模和預測：按分銷渠道
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按藥物類型
    • LAMEA 市場規模和預測：按應用分類
    • LAMEA 市場規模和預測：按分銷渠道
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • GlaxoSmithKline Plc
  • Sanofi
  • Novartis AG
  • Pfizer Inc
  • Merck & Co. Inc
  • Dr. Reddy's Laboratories Ltd
  • Cipla
  • Johnson & Johnson
  • Torrent Pharmaceuticals Ltd
  • Acacia Pharma Group
Product Code: A00336

The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031, registering a CAGR of 6.1% from 2022 to 2031.

Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.

Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.

Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.

Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.

However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.

The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy's Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Antihistamines
  • Serotonin Receptor Antagonists
  • Dopamine Receptor Antagonists
  • Neurokinin Receptor Antagonists
  • Anticholinergics
  • Other Drug Types

By Application

  • Chemotherapy
  • Post Operative Surgery
  • Pregnancy and Gatroenteritis
  • Other Applications

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • GlaxoSmithKline Plc
    • Sanofi
    • Novartis AG
    • Pfizer Inc
    • Merck & Co. Inc
    • Dr. Reddy's Laboratories Ltd
    • Cipla
    • Johnson & Johnson
    • Torrent Pharmaceuticals Ltd
    • Acacia Pharma Group

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Antihistamines
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Serotonin Receptor Antagonists
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Dopamine Receptor Antagonists
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Neurokinin Receptor Antagonists
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Anticholinergics
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country
  • 4.7 Other Drug Types
    • 4.7.1 Key market trends, growth factors and opportunities
    • 4.7.2 Market size and forecast, by region
    • 4.7.3 Market analysis by country

CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Chemotherapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Post Operative Surgery
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Pregnancy and Gatroenteritis
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Other Applications
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Retail Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Hospital Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: ANTIEMETICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Type
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Type
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Type
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Type
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Type
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Type
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Type
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Type
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Type
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Type
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Type
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Market size and forecast, by Drug Type
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Market size and forecast, by Drug Type
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Drug Type
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Drug Type
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Type
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Type
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Type
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Type
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Type
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Type
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Type
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 GlaxoSmithKline Plc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Sanofi
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Novartis AG
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Pfizer Inc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Merck & Co. Inc
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Dr. Reddy's Laboratories Ltd
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Cipla
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Johnson & Johnson
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Torrent Pharmaceuticals Ltd
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Acacia Pharma Group
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 2. ANTIEMETICS MARKET, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. ANTIEMETICS MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. ANTIEMETICS MARKET, FOR SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. ANTIEMETICS MARKET FOR SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. ANTIEMETICS MARKET, FOR DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. ANTIEMETICS MARKET FOR DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. ANTIEMETICS MARKET, FOR NEUROKININ RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. ANTIEMETICS MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. ANTIEMETICS MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. ANTIEMETICS MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. ANTIEMETICS MARKET, FOR OTHER DRUG TYPES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. ANTIEMETICS MARKET FOR OTHER DRUG TYPES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. GLOBAL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 15. ANTIEMETICS MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. ANTIEMETICS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. ANTIEMETICS MARKET, FOR POST OPERATIVE SURGERY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. ANTIEMETICS MARKET FOR POST OPERATIVE SURGERY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. ANTIEMETICS MARKET, FOR PREGNANCY AND GATROENTERITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. ANTIEMETICS MARKET FOR PREGNANCY AND GATROENTERITIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. ANTIEMETICS MARKET, FOR OTHER APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. ANTIEMETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. GLOBAL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 24. ANTIEMETICS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. ANTIEMETICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. ANTIEMETICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. ANTIEMETICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. ANTIEMETICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. ANTIEMETICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. ANTIEMETICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 36. U.S. ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 37. U.S. ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. CANADA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 39. CANADA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 40. CANADA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 49. GERMANY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 50. GERMANY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. FRANCE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 52. FRANCE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 53. FRANCE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. UK ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 55. UK ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 56. UK ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. ITALY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 58. ITALY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 59. ITALY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 61. SPAIN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 62. SPAIN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 64. REST OF EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 65. REST OF EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 70. CHINA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 71. CHINA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 72. CHINA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. JAPAN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 74. JAPAN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 75. JAPAN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 76. INDIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 78. INDIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 81. AUSTRALIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH KOREA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 94. BRAZIL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 97. SAUDI ARABIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH AFRICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 103. REST OF LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 104.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 105.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 106.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 107.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 108.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 109.SANOFI: COMPANY SNAPSHOT
  • TABLE 110.SANOFI: OPERATING SEGMENTS
  • TABLE 111.SANOFI: PRODUCT PORTFOLIO
  • TABLE 112.SANOFI: NET SALES,
  • TABLE 113.SANOFI: KEY STRATERGIES
  • TABLE 114.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 115.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 116.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 117.NOVARTIS AG: NET SALES,
  • TABLE 118.NOVARTIS AG: KEY STRATERGIES
  • TABLE 119.PFIZER INC: COMPANY SNAPSHOT
  • TABLE 120.PFIZER INC: OPERATING SEGMENTS
  • TABLE 121.PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 122.PFIZER INC: NET SALES,
  • TABLE 123.PFIZER INC: KEY STRATERGIES
  • TABLE 124.MERCK & CO. INC: COMPANY SNAPSHOT
  • TABLE 125.MERCK & CO. INC: OPERATING SEGMENTS
  • TABLE 126.MERCK & CO. INC: PRODUCT PORTFOLIO
  • TABLE 127.MERCK & CO. INC: NET SALES,
  • TABLE 128.MERCK & CO. INC: KEY STRATERGIES
  • TABLE 129.DR. REDDY'S LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 130.DR. REDDY'S LABORATORIES LTD: OPERATING SEGMENTS
  • TABLE 131.DR. REDDY'S LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 132.DR. REDDY'S LABORATORIES LTD: NET SALES,
  • TABLE 133.DR. REDDY'S LABORATORIES LTD: KEY STRATERGIES
  • TABLE 134.CIPLA: COMPANY SNAPSHOT
  • TABLE 135.CIPLA: OPERATING SEGMENTS
  • TABLE 136.CIPLA: PRODUCT PORTFOLIO
  • TABLE 137.CIPLA: NET SALES,
  • TABLE 138.CIPLA: KEY STRATERGIES
  • TABLE 139.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 140.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 141.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 142.JOHNSON & JOHNSON: NET SALES,
  • TABLE 143.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 144.TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 145.TORRENT PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 146.TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 147.TORRENT PHARMACEUTICALS LTD: NET SALES,
  • TABLE 148.TORRENT PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 149.ACACIA PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 150.ACACIA PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 151.ACACIA PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 152.ACACIA PHARMA GROUP: NET SALES,
  • TABLE 153.ACACIA PHARMA GROUP: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.ANTIEMETICS MARKET SEGMENTATION
  • FIGURE 2.ANTIEMETICS MARKET,2021-2031
  • FIGURE 3.ANTIEMETICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.ANTIEMETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.ANTIEMETICS MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEROTONIN RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DOPAMINE RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUROKININ RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICHOLINERGICS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHER DRUG TYPES ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 19.ANTIEMETICS MARKET,BY APPLICATION,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF POST OPERATIVE SURGERY ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND GATROENTERITIS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 24.ANTIEMETICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
  • FIGURE 28.ANTIEMETICS MARKET BY REGION,2021
  • FIGURE 29.U.S. ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 30.CANADA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 31.MEXICO ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 32.GERMANY ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 33.FRANCE ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 34.UK ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 35.ITALY ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 36.SPAIN ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF EUROPE ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 38.CHINA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 39.JAPAN ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 40.INDIA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 41.AUSTRALIA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH KOREA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF ASIA-PACIFIC ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 44.BRAZIL ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 45.SAUDI ARABIA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH AFRICA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF LAMEA ANTIEMETICS MARKET,2021-2031($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 55.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 57.PFIZER INC.: NET SALES ,($MILLION)
  • FIGURE 58.MERCK & CO. INC.: NET SALES ,($MILLION)
  • FIGURE 59.DR. REDDY'S LABORATORIES LTD.: NET SALES ,($MILLION)
  • FIGURE 60.CIPLA.: NET SALES ,($MILLION)
  • FIGURE 61.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 62.TORRENT PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
  • FIGURE 63.ACACIA PHARMA GROUP.: NET SALES ,($MILLION)